Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?

Nature Clinical Practice Oncology volume 2, pages 284–285 (2005)Cite this article

boxed-textChung KY et al. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23: 1803–1810

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cunningham D et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345

    Article  CAS  Google Scholar 

  2. Saltz LB et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201–1208

    Article  CAS  Google Scholar 

  3. Lenz HJ et al. (2004) Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. ASCO Meeting Abstracts 22: 3510

    Google Scholar 

  4. Scartozzi M et al. (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22: 4720–4726

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. the Chief of the Department of Oncology at the Vall d'Hebron University Hospital in Barcelona, Spain

    José Baselga

Authors
  1. José Baselga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to José Baselga.

Ethics declarations

Competing interests

J Baselga has received honoraria from Merck KGaA.

Glossary

MSKCC

Memorial Sloan-Kettering Cancer Center

RT-PCR

Reverse transcriptase polymerase chain reaction; a variation of the PCR technique in which cDNA is made from RNA via reverse transcription and the cDNA is then amplified using standard PCR protocols

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baselga, J. Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?. Nat Rev Clin Oncol 2, 284–285 (2005). https://doi.org/10.1038/ncponc0165

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0165

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing